Publication

Video

Supplements and Featured Publications

Utilizing Tumor Metabolism in Solid Malignancies
Volume1
Issue 1

Dr. Rizvi on the Rationale to Evaluate Telaglenastat in KEAP1/NRF2-Mutant NSCLC

Naiyer A. Rizvi, MD, discusses the rationale to evaluate the investigational glutaminase inhibitor telaglenastat in patients with non–small cell lung cancer who harbor KEAP1 or NRF2 mutations.

Naiyer A. Rizvi, MD, Price Family ​Professor of ​Medicine, director, Thoracic Oncology, co-director, Cancer Immunotherapy, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, research director, Price Family Comprehensive Center for Chest Care, NewYork-Presbyterian Hospital, discusses the rationale to evaluate the investigational glutaminase inhibitor telaglenastat (CB-839) in patients with non–small cell lung cancer (NSCLC) who harbor KEAP1 or NRF2 mutations.

KEAP1-mutant tumors are thought to be highly proliferative and largely dependent on glutamine to complete anabolic metabolism, says Rizvi. Moreover, fast-growing tumors have significant anabolic metabolism requirements. These requirements can be dependent on glucose or glutamine, depending on the body’s anabolic state.

Glutamine is metabolized to glutamate for DNA protein synthesis, Rizvi explains. Additionally, glutamine is converted to glutathione, which can protect cancer cells from oxidative stress, says Rizvi. 

As such, preclinical models with telaglenastat in patients with KEAP1/NRF2-mutant NSCLC have shown that inhibiting glutamine metabolism with an agent such as telaglenastat can increase the oxidative stress within the cancer cells. Giving telaglenastat in combination with standard of care options, such as pembrolizumab (Keytruda), carboplatin, and pemetrexed, may elicit improved tumor destruction, concludes Rizvi.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity